{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '128', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.1.9', 'Source Documents', 'Source documents provide evidence for the existence of the participant and substantiate the', 'integrity of the data collected. The investigator/institution should maintain adequate and', 'accurate source documents and study records that include all pertinent observations on each', \"of the site's participants. Source documents and data should be attributable, legible,\", 'contemporaneous, original, accurate, and complete. Changes to source data should be', 'traceable, should not obscure the original entry, and should be explained if necessary (eg, via', \"an audit trail). Source documents are filed at the investigator's site.\", 'Data reported on the CRF or entered in the eCRF that are transcribed from source documents', 'must be consistent with the source documents or the discrepancies must be explained. The', 'investigator/institution may need to request previous medical records or transfer records,', 'depending on the study. Also, current medical records must be available.', '10.1.10 Study and Site Closure', 'The Sponsor or its designee may stop the study or study site participation in the study for', 'medical, safety, regulatory, administrative, or other reasons consistent with applicable laws,', 'regulations, and GCP.', 'In the event the Sponsor prematurely terminates a particular study site, the Sponsor will', \"promptly notify that study site's IRB/IEC.\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '129', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.2', 'Appendix 2: Clinical Laboratory Tests', 'The laboratory tests detailed in Table 11 will be performed by the local laboratory.', 'Protocol-specific requirements for inclusion or exclusion of participants are detailed', 'in Section 5 of the protocol.', 'Additional tests may be performed at any time during the study if determined', 'necessary by the investigator or required by local regulations.', 'Pregnancy testing requirements for study inclusion are described in Section 5.1 and', 'Section 8.3.5.2.', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at monthly intervals during intervention.', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at the end of relevant systemic exposure and correspond with the time', 'frame for female participant contraception in Section 5.1, Inclusion Criteria.', 'Additional serum or urine pregnancy tests may be performed, as determined', 'necessary by the investigator or required by local regulation, to establish the absence', \"of pregnancy at any time during the participant's participation in the study.\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '130', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 11', 'Protocol-Required Safety Laboratory Assessments', 'Comprehensive', 'Hematology', 'Urinalysis', 'Other', 'Chemistry Panel', 'Hematocrit', 'Albumin', 'Blood', 'FSHa', 'Hemoglobin', 'Alkaline phosphatase', 'Glucose', 'Pregnancy test (highly', 'sensitive serum or urine)', 'human chorionic', 'gonadotropin (hCG)b', 'Platelet count', 'ALT', 'Protein', 'PT/INR and aPTT/PTT', 'RBC', 'AST', 'Specific gravity', 'Total T3 (or FT3), total T4', 'WBC count with', '(or FT4), and TSHC,d', 'differential (absolute or', 'CO2 or bicarbonatee', 'Microscopic', 'HIV testing', 'percentage):', 'Calcium', 'examination, if', 'Hepatitis B and C testingt,g', 'Neutrophils', 'Chloride', 'abnormal results are', 'Blood for genetic analysis', 'Lymphocytes', 'noted', 'Monocytes', 'Creatinine', 'Eosinophils', 'Glucose', 'Basophils', 'Magnesium', 'Phosphorus', 'Potassium', 'Blood for serum', 'biomarkers', 'Sodium', 'Blood for RNA analysis', 'Total bilirubin', 'Blood for circulating tumor', 'nucleic acids', 'Direct bilirubinh', 'Blood for plasma', 'Total protein', 'biomarkers', 'BUN or urea\u00b9', 'Amylase', 'Lipase', 'Abbreviations: ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate', 'aminotransferase; BUN = blood urea nitrogen; C1D1 = Cycle 1 Day 1; CO2 = carbon dioxide; FSH = follicle-', 'stimulating hormone; FT3 = free triiodothyronine; FT4 = free thyroxine; HIV = human immunodeficiency', 'virus; INR = international normalized ratio; PT = prothrombin time; PTT = partial thromboplastin time;', 'RBC = red blood cells; SOC = standard of care; T3 = triiodothyronine; T4 = thyroxine;', 'TSH = thyroid-stimulating hormone; WBC = white blood cell; WOCBP = women of childbearing potential.', 'a', 'As needed, FSH to be performed at screening to confirm postmenopausal status.', 'b', 'Perform on WOCBP only 24 hours before first dose. Pregnancy tests must be repeated before every cycle.', 'c', 'T3 is preferred; if not available, free T3 may be tested.', 'd', 'Participants may be dosed in subsequent cycles after C1D1 while thyroid function tests are pending.', 'e', 'Bicarbonate only if available as SOC in the region.', 'f', 'If mandated by local health authority.', 'g', 'Hepatitis B surface antigen (HBsAg) or hepatitis B virus (HBV)-DNA. Hepatitis C virus (HCV)-RNA', '(qualitative) or HCV antibody.', 'h', 'If total bilirubin is elevated above the upper limit of normal.', 'i', 'BUN or urea (one or the other should be collected per institutional standard).', 'The investigator (or medically qualified designee) must document their review of each', 'laboratory safety report.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}